Literature DB >> 28365942

Development, characterization and evaluation of doxorubicin nanostructured lipid carriers for prostate cancer.

Hong-Wei Zhang1, Qiang Dang, Zheng-Wei Zhang, Fu-Shun Wu.   

Abstract

PURPOSE: The purpose of this study was to develop an optimised formulation for a nanostructured lipid carrier (NLC) loaded with doxorubicin.
METHODS: A doxorubicin-loaded NLC was prepared using an emulsification solidification method. The Box-Behnken design response surface methodology was used to optimise formulations of the doxorubicin-loaded NLC.
RESULTS: The drug entrapment efficiency, drug loading efficiency, particle size, and zeta potential of the doxorubicin- loaded NLC were 74.18%, 13.28%, 170 nm, and -14.8 mV, respectively. Transmission electron microscopy of the optimised NLC showed spherical particles. Furthermore, the doxorubicin-loaded NLC was found to exhibit good therapeutic efficacy with remarkably improved oral bioavailability of doxorubicin.
CONCLUSION: The NLC system demonstrated potential for the targeted delivery of doxorubicin in prostate cancer.

Entities:  

Mesh:

Substances:

Year:  2017        PMID: 28365942

Source DB:  PubMed          Journal:  J BUON        ISSN: 1107-0625            Impact factor:   2.533


  3 in total

Review 1.  Progress and Principle of Drug Nanocrystals for Tumor Targeted Delivery.

Authors:  Meng Bai; Mingshi Yang; Junbo Gong; Hui Xu; Zhenping Wei
Journal:  AAPS PharmSciTech       Date:  2021-12-28       Impact factor: 3.246

Review 2.  Antineoplastics Encapsulated in Nanostructured Lipid Carriers.

Authors:  Gustavo Henrique Rodrigues da Silva; Ludmilla David de Moura; Fabíola Vieira de Carvalho; Gabriela Geronimo; Talita Cesarim Mendonça; Fernando Freitas de Lima; Eneida de Paula
Journal:  Molecules       Date:  2021-11-17       Impact factor: 4.411

3.  Combination prostate cancer therapy: Prostate-specific membranes antigen targeted, pH-sensitive nanoparticles loaded with doxorubicin and tanshinone.

Authors:  Guanxing Sun; Kai Sun; Jie Sun
Journal:  Drug Deliv       Date:  2021-12       Impact factor: 6.419

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.